Search Results

The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.

Checkpoint Therapeutics, Inc. today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab.

RedHill Biopharma Ltd. announced the issue of a new Chinese patent notice of allowance for opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response, providing protection for opaganib’s potential use with a range of approved and in-development immune checkpoint inhibitors across a growing range of indications through 2040.

Checkpoint Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET.